Chris Howerton
Stock Analyst at Jefferies
(2.62)
# 2,084
Out of 5,150 analysts
68
Total ratings
43.4%
Success rate
19.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $8.20 | -8.54% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $63.13 | +98.00% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.65 | +20.30% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.65 | +142.42% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.51 | +298.41% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.65 | +21,233.33% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $18.36 | +3,821.57% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.14 | -76.64% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $20.16 | -50.40% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $19.86 | +101.41% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $28.54 | +113.74% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $164.08 | -45.15% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.33 | +5,927.73% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $29.54 | +123.43% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.95 | +344.44% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.08 | +1,844.44% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.61 | +3,491.84% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $23.39 | -10.22% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $9.13 | +6,252.68% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.16 | +2,677.78% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $35.69 | -55.17% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $94.83 | -71.53% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $1.26 | +95,138.10% | 1 | May 26, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $8.20
Upside: -8.54%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $63.13
Upside: +98.00%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.65
Upside: +20.30%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.65
Upside: +142.42%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.51
Upside: +298.41%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.65
Upside: +21,233.33%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $18.36
Upside: +3,821.57%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.14
Upside: -76.64%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $20.16
Upside: -50.40%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $19.86
Upside: +101.41%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $28.54
Upside: +113.74%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $164.08
Upside: -45.15%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.33
Upside: +5,927.73%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $29.54
Upside: +123.43%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $4.95
Upside: +344.44%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.08
Upside: +1,844.44%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.61
Upside: +3,491.84%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $23.39
Upside: -10.22%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $9.13
Upside: +6,252.68%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.16
Upside: +2,677.78%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $35.69
Upside: -55.17%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $94.83
Upside: -71.53%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $1.26
Upside: +95,138.10%